Drug
INS50589 Intravenous Infusion
INS50589 Intravenous Infusion is a pharmaceutical drug with 2 clinical trials. Historical success rate of 50.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(50%)
Phase Distribution
Ph phase_2
1
50%
Ph phase_1
1
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Terminated(1)
Detailed Status
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
completed150%
terminated150%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_2
Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass
NCT00316212
completedphase_1
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
NCT00099450
Clinical Trials (2)
Showing 2 of 2 trials
NCT00316212Phase 2
Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass
NCT00099450Phase 1
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2